Clinical Trial Update: Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy study evaluating the combination of CC-486 (oral azacitidine) with MK-3475 (pembrolizumab) in locally advanced or metastatic non-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CC-486 (azacitidine)
• MK-3475 (pembrolizumab)

Snippet

Sponsor: Celgene | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2018-05-14